268 related articles for article (PubMed ID: 19442052)
1. Overcoming drug resistance by enhancing apoptosis of tumor cells.
Giménez-Bonafé P; Tortosa A; Pérez-Tomás R
Curr Cancer Drug Targets; 2009 May; 9(3):320-40. PubMed ID: 19442052
[TBL] [Abstract][Full Text] [Related]
2. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
Huerta S; Heinzerling JH; Anguiano-Hernandez YM; Huerta-Yepez S; Lin J; Chen D; Bonavida B; Livingston EH
J Surg Res; 2007 Sep; 142(1):184-94. PubMed ID: 17603079
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
4. Cancer and Apoptosis.
Chaudhry GE; Akim AM; Sung YY; Muhammad TST
Methods Mol Biol; 2022; 2543():191-210. PubMed ID: 36087269
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.
Drosopoulos K; Pintzas A
Expert Opin Ther Targets; 2007 May; 11(5):641-59. PubMed ID: 17465723
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
7. Anti-apoptotic mechanisms of drug resistance in cancer.
Wilson TR; Johnston PG; Longley DB
Curr Cancer Drug Targets; 2009 May; 9(3):307-19. PubMed ID: 19442051
[TBL] [Abstract][Full Text] [Related]
8. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
Shahar N; Larisch S
Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
[TBL] [Abstract][Full Text] [Related]
10. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
12. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
13. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
14. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
15. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
16. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.
Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N
Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781
[TBL] [Abstract][Full Text] [Related]
17. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
19. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S
Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919
[TBL] [Abstract][Full Text] [Related]
20. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
